-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On November 16, Haisco issued an announcement that the clinical application of the company's innovative drug HSK31679 tablets was accepted by the State Food and Drug Administration
HSK31679 tablet is a highly selective thyroid hormone β receptor (THR-β) agonist independently developed by Haisco.
Preclinical studies have shown that HSK31679 has good pharmacodynamic effects in hypercholesterolemia and NASH models, and has a good development prospect.
Prior to this, the THR-β agonist ASC41 of Golly Pharmaceuticals has been approved for clinical use in the treatment of adult non-alcoholic steatohepatitis